I am not oligometastatic, dammit! But this could really be something worth trying! It is, at least from preclinical studies, a more targeted version of the previous Actinium based therapies.
The ACCEL trial is a Phase 1 clinical study testing Actinium-225-labeled PSMA-62, a targeted radioligand therapy for oligometastatic hormone-sensitive prostate cancer and metastatic castration resistant prostate cancer.
This therapy combines Actinium-225, a powerful alpha-emitting radioisotope, with PSMA-62, a molecule that binds to Prostate-Specific Membrane Antigen (PSMA) on cancer cells.
By delivering precise radiation, it aims to destroy cancer cells while sparing healthy tissue. Early results show strong anti-tumor effects with manageable side effects.